Cetya Therapeutics, Inc. (“Cetya”) was formed in 2012 to commercialize histone deacetylase inhibitors (HDACi) based on largazole. Some of these analogs have bifunctional modifications and the potential to target specific cell types or tumors.
This is unique in the HDACi space and, together with potency and selectivity, differentiates Cetya’s compounds. Cetya holds exclusive license rights to the largazole analog intellectual property created by Dr. Robert M. Williams at Colorado State University. More than 40 largazole analogs have been synthesized, some with best-in-class profiles as HDACi. Biochemical and cell-based potency, upregulation of fetal hemoglobin expression and in-vivo anti-cancer activity have been demonstrated.
As a drug class, HDACis have been demonstrated to be effective in treating certain cancers and thought leaders in epigenetics believe that this class of compounds may have much broader application in treating hemoglobinopathies, chronic inflammation, neurological disorders, fibrotic diseases, and enhance the efficacy of antiretroviral therapy for HIV by reactivating latent pools of virus. All of these indications will be investigated as the preclinical dataset around Cetya’s analogs matures.